EU Supports Microbiome R&D Via Enterome
France's leading microbiome company, Enterome, has raised €32m in a series D financing and secured a €40m loan facility from the European Investment Bank to advance a small molecule and a potential cancer vaccine approach into early-stage clinical studies.
You may also be interested in...
Finance Watch: BioGeneration Ventures, Autobahn Labs Offer New Start-Up Resources
Private Company Edition: BioGeneration closed a €105m ($119m) fund to continue backing new European companies, while Samsara BioCapital, Evotec and KCK Ltd. launched the virtual incubator Autobahn Labs. Also, Poseida, Annexon and Goldfinch close $100m-plus VC rounds.
Lundbeck Leads $50m Fund Raise For CRISPR Microbiome StartUp
A Danish company with a novel approach to gene editing for antibacterials has raised $50m in a series A round, using the cash injection to advance its ambition to be testing drug candidates in humans by 2021.
Takeda And Enterome To Jointly Mine The Microbiome
In a deal that further expands its credentials, French company Enterome has inked an alliance with Japan's Takeda to conduct research and develop novel therapeutics aimed at microbiome targets thought to play crucial roles in gastrointestinal disorders.